Recent data in MDS, using TP53 as a prototype, has highlighted the importance of assessment of both somatic mutations and SVs (deletions, CN-LOH, rearrangements) in genomic regions of interest for accurate prognostication [16, 17]. This evidence concerns the gene TP53 and myelodysplastic syndrome.